Solid Biosciences (SLDB) Set to Announce Quarterly Earnings on Monday

Solid Biosciences (NASDAQ:SLDB) is anticipated to release its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to post earnings of ($0.37) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Solid Biosciences (NASDAQ:SLDB) last posted its earnings results on Thursday, August 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.08. On average, analysts expect Solid Biosciences to post ($1.66) EPS for the current fiscal year and ($1.70) EPS for the next fiscal year.

Solid Biosciences Price Performance

Shares of NASDAQ:SLDB opened at $6.20 on Friday. Solid Biosciences has a 12-month low of $3.79 and a 12-month high of $11.45. The business has a 50 day moving average of $7.81 and a two-hundred day moving average of $7.64.

Wall Street Analyst Weigh In

SLDB has been the topic of a number of analyst reports. Cantor Fitzgerald raised their price objective on shares of Solid Biosciences from $16.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Wall Street Zen upgraded shares of Solid Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 4th. UBS Group initiated coverage on shares of Solid Biosciences in a report on Wednesday, October 14th. They set a “buy” rating and a $20.00 price target on the stock. Truist Financial increased their price target on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Finally, Royal Bank Of Canada assumed coverage on shares of Solid Biosciences in a research report on Wednesday, September 16th. They set an “outperform” rating and a $18.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.79.

Solid Biosciences Company Profile

Solid Biosciences Inc (NASDAQ: SLDB) is a biotechnology company focused on developing gene therapies for neuromuscular and other serious genetic diseases. The company uses adeno-associated virus (AAV) delivery technologies and genetic medicine approaches to develop treatments intended to address the underlying causes of disease.

Its lead investigational program, SGT-003, is being developed as a gene therapy for Duchenne muscular dystrophy, a severe X-linked muscle-wasting disorder. Solid Biosciences also has additional preclinical and clinical programs targeting other neuromuscular conditions, including diseases associated with defects in muscle proteins.